Back

A microglia-CD4+ T cell partnership generates protective anti-tumor immunity to glioblastoma

Chen, D.; Varanasi, S. K.; Hara, T.; Traina, K.; McDonald, B.; Farsakoglu, Y.; Clanton, J.; Xu, S.; Mann, T. H.; Du, V.; Chung, H. K.; Xu, Z.; Tripple, V.; Casillas, E.; Ma, S.; O Connor, C.; Yang, Q.; Zheng, Y.; Hunter, T.; Lemke, G.; Kaech, S. M.

2022-08-14 immunology
10.1101/2022.08.12.502093 bioRxiv
Show abstract

The limited efficacy of immunotherapies against glioblastoma illustrates the urgent need to better understand the interactions between the central nervous system and the immune system. Here, we showed that a protective response to CTLA-4 therapy depended on a mutualistic relationship between microglia and CD4+ T cells. Suppression of gliomas by CD4+ T cells did not require tumor-intrinsic MHC-II expression, but rather was dependent on the selective expression of MHC-II and antigen presentation by local microglia that in turn, sustained CD4+ T cell tumoricidal effector functions. CD4+ T cell secretion of IFN{gamma} made the glioma cells vulnerable to enhanced tumor surveillance and phagocytosis by microglia via the AXL/MER tyrosine kinase receptors that were necessary for tumor suppression. This work illustrates a novel partnership between CD4+ T cells and microglia that unleashes the tumoricidal properties of microglia that can be harnessed to improve immunotherapies for glioblastoma.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.